Osaka University scientists said it has carried out the world’s first transplant of cardiac muscle cells created from iPS cells in a physician-initiated clinical trial.
Prof. Yoshiki Sawa, Department of Cardiology, has been using iPS cells to develop cell therapies for the heart.
The project has been conducted with funding from the Japan Agency for Medical Research and Development.
Based on the success in animal experiments, last year, the Sawa group submitted a clinical research plan to used cells manufactured from iPS cells to treat patients with heart disease. Due to the nature of the therapy, the plan was categorized as class I (high risk) regenerative medicine.
This past May 16th, the plan was conditionally approved by the Ministry of Health, Labour and Welfare.